Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
Deals In Depth: November 2020 :: Generics Bulletin
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Biogen
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
SY Investing on Twitter: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE- 217 showed mean reduction of 12.6 in HAM-D total
Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics surges 70% after depression drug breakthrough
sage-10k_20191231.htm
Discovering, developing and delivering life-changing therapies to treat rare central nervous system disorders.
GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia | BioSpace
BioWorld
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
sage-10k_20181231.htm
